Ganga Pharmaceuticals Ltd.

BSE: 539680 SECTOR: Pharmaceuticals & Drugs

6
-1.5 (-20%)
BSE: 05 Jul 4:00 PM

Price Summary

Today's High

₹ 7.8

Today's Low

₹ 6

52 Week High

₹ 12

52 Week Low

₹ 6

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.

Company Essentials

Market Cap

2.44 Cr.

Enterprise Value

3.9 Cr.

No. of Shares

0.41 Cr.

P/E

121.95

P/B

0.46

Face Value

₹ 10

Div. Yield

0%

Book Value (TTM)

₹  13.18

CASH

0.01 Cr.

DEBT

1.47 Cr.

Promoter Holding

66.71%

EPS (TTM)

₹  0.05

Sales Growth

-8.44%

ROE

3.59 %

ROCE

7.18 %

Profit Growth

0.87 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Ratios

Sales Growth

1 Year-8.44%
3 Year0.75%
5 Year3.39%

Profit Growth

1 Year0.87%
3 Year36.54%
5 Year41.31%

ROE%

1 Year3.59%
3 Year3.07%
5 Year2.43%

ROCE %

1 Year7.18%
3 Year6.75%
5 Year6.66%

Debt/Equity

0.2755

Price to Cash Flow

-7.95

Interest Cover Ratio

2.05261283522912

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2021 66.71 0
Mar 2021 66.71 0
Dec 2020 66.71 0
Sep 2020 66.71 0
Jun 2020 66.71 0
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy liquidity position with current ratio of 2.73372046067675.
  • The company has a high promoter holding of 66.71%.

 Limitations

  • The company has shown a poor revenue growth of 0.752269064399402% for the Past 3 years.
  • Company has a poor ROE of 3.06653302250937% over the past 3 years.
  • Company has negative cash flow from operations of -0.3064044.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2018
Net Sales 1.95
Total Expenditure 1.73
Operating Profit 0.21
Other Income 0.07
Interest 0.14
Depreciation 0.04
Exceptional Items 0
Profit Before Tax 0.11
Tax 0.03
Profit After Tax 0.09
Adjusted EPS (Rs) 0.21

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Net Sales 2.63 3.01 3.05 3.36 3.08
Total Expenditure 2.33 2.7 2.73 2.94 2.69
Operating Profit 0.3 0.31 0.32 0.42 0.39
Other Income 0.14 0.16 0.15 0.14 0.17
Interest 0.33 0.32 0.28 0.25 0.24
Depreciation 0.04 0.04 0.06 0.05 0.05
Exceptional Items 0 0 0 0 0
Profit Before Tax 0.07 0.11 0.13 0.26 0.26
Tax 0.02 0.03 0.03 0.07 0.07
Net Profit 0.05 0.07 0.09 0.19 0.19
Adjusted EPS (Rs.) 0.12 0.18 0.23 0.46 0.46

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Equity and Liabilities
Share Capital 4.06 4.06 4.06 4.06 4.06
Total Reserves 0.74 0.81 0.91 1.09 1.29
Borrowings 1.32 1.1 0.87 0.66 0.59
Other N/C liabilities -0.01 0 0 0 0.01
Current liabilities 1.21 1.63 2.39 1.94 1.62
Total Liabilities 7.33 7.61 8.23 7.76 7.57
Assets
Net Block 0.62 0.62 0.82 0.8 0.76
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0.5 0 0 0.09 0.09
Loans & Advances 1.33 2.75 2.77 2.52 2.3
Other N/C Assets 0.3 0 0 0 0
Current Assets 4.57 4.23 4.63 4.35 4.42
Total Assets 7.33 7.61 8.23 7.76 7.57
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020
Profit from operations 0.07 0.11 0.13 0.26 0.26
Adjustment 0.04 0.19 0.18 0.15 0.11
Changes in Assets & Liabilities -1.15 -0.21 -0.03 -0.23 -0.61
Tax Paid -0.01 -0.04 -0.04 -0.06 -0.06
Operating Cash Flow -1.05 0.05 0.24 0.11 -0.31
Investing Cash Flow -0.83 0.62 -0.14 0.28 0.37
Financing Cash Flow 1.9 -0.33 -0.36 -0.45 -0.29
Net Cash Flow 0.02 0.33 -0.26 -0.05 -0.22

Corporate Actions

Investors Details

PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Promoters 66.71 66.71 66.71 66.71 66.71
amit shukla 1.88 1.88 1.88 1.88 1.88
anagh bharat sharma 6.4 6.4 6.4 6.4 6.4
savitri sharma 5.63 5.63 5.63 5.63 5.63
srijna sharma 5.96 5.96 5.96 5.96 5.96
usha shukla 2.34 2.34 2.34 2.34 2.34
ankita amit shukla 0.98 0.98 0.98 0.98 0.98
amit shukla 1.88 1.88 1.88 1.88 1.88
anagh bharat sharma 6.4 6.4 6.4 6.4 6.4
bharat brijmohan sharma h... 4.68 4.68 4.68 4.68 4.68
brijmohan sharma huf 8.61 8.61 8.61 8.61 8.61
savitri sharma 5.63 5.63 5.63 5.63 5.63
sharma bharat b 30.23 30.23 30.23 30.23 30.23
srijna sharma 5.96 5.96 5.96 5.96 5.96
usha shukla 2.34 2.34 2.34 2.34 2.34
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
Public 33.29 33.29 33.29 33.29 33.29
babalbhai manilal patel 3.35 3.35 3.35 3.35 0
sanjay dhansukhlal shah 1.97 1.97 1.97 1.97 0
anju ritesh agarwal 1.18 1.18 1.18 1.18 0
niraj agarwal 1.38 0 0 0 0
rameshchand rawatmal agar... 1.38 1.38 1.38 1.38 0
akshay amarnath sharma . 1.77 0 2.17 2.17 0
kiran amarnath sharma 1.18 1.18 1.18 1.18 0
shweta akash sharma 1.38 0 0 0 0
akshay amarnath sharma 0 2.17 0 0 0
niraj rameshchandra agarw... 0 1.38 1.38 1.38 0
PARTICULARS Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021
FII/DII 0 0 0 0 0
akshay amarnath sharma 0 0 0 0 2.17
anju ritesh agarwal 0 0 0 0 1.18
babalbhai manilal patel 0 0 0 0 3.35
kiran amarnath sharma 0 0 0 0 1.18
niraj rameshchandra agarw... 0 0 0 0 1.38
rameshchand rawatmal agar... 0 0 0 0 1.38
sanjay dhansukhlal shah 0 0 0 0 1.97

Ratings & Research Reports

No Credit and Research reports exist for this company.
Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.
Report us

Ganga Pharma. Stock Price Analysis and Quick Research Report. Is Ganga Pharma. an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Ganga Pharma. and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs -0.3064044 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Ganga Pharma. has a Debt to Equity ratio of 0.2755 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Ganga Pharma. , the EPS growth was 0.868243976557413 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Ganga Pharma. has OPM of 12.552402146553 % which is a bad sign for profitability.
     
  • ROE: Ganga Pharma. have a poor ROE of 3.59325784149821 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Ganga Pharma.

X